文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

围手术期干预预防术后肺部并发症:系统评价与Meta分析

Perioperative interventions for prevention of postoperative pulmonary complications: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2020-03-11
一句话结论针对非心脏手术成人患者,低至中等质量证据支持多种围手术期干预可降低术后肺部并发症,但无高质量证据。

该系统评价与Meta分析纳入117项随机对照试验共21940例非心脏手术成人患者,评估11类围手术期干预对术后肺部并发症(PPCs)的影响。95项试验(18062例)进入Meta分析,未发现高质量证据;7种干预有低或中等质量证据提示可能降低PPCs:加速康复路径(RR 0.35)、预防性黏液溶解剂(RR 0.40)、术后持续气道正压通气(RR 0.49)、肺保护性术中通气(RR 0.52)、预防性呼吸物理治疗(RR 0.55)、硬膜外镇痛(RR 0.77)和目标导向血流动力学治疗(RR 0.87)。中等质量证据显示激励式肺量计无获益。作者认为临床医生可重新评估围手术期管理路径,但许多干预仍需低偏倚风险的新试验证实。

要点

  • 加速康复路径与PPCs降低相关(RR 0.35,95%CI 0.21-0.58),证据质量低或中等。
  • 预防性黏液溶解剂(RR 0.40,95%CI 0.23-0.67)和术后持续气道正压通气(RR 0.49,95%CI 0.24-0.99)可能降低PPCs。
  • 肺保护性术中通气(RR 0.52,95%CI 0.30-0.88)和预防性呼吸物理治疗(RR 0.55,95%CI 0.32-0.93)可能降低PPCs。
  • 硬膜外镇痛(RR 0.77,95%CI 0.65-0.92)和目标导向血流动力学治疗(RR 0.87,95%CI 0.77-0.98)可能降低PPCs。
  • 中等质量证据显示激励式肺量计对预防PPCs无获益;未发现高质量证据。

适用人群与场景

  • 接受非心脏手术的成人患者,干预在术前、术中或术后实施。
  • 仅纳入报告PPCs临床诊断标准的随机对照试验;排除研究手术技术或生理/生化结局的研究。

处置流程与药物剂量

  • 加速康复路径:与PPCs降低相关(RR 0.35,95%CI 0.21-0.58),证据质量低或中等。
  • 预防性黏液溶解剂:与PPCs降低相关(RR 0.40,95%CI 0.23-0.67),证据质量低或中等。
  • 术后持续气道正压通气:与PPCs降低相关(RR 0.49,95%CI 0.24-0.99),证据质量低或中等。
  • 肺保护性术中通气:与PPCs降低相关(RR 0.52,95%CI 0.30-0.88),证据质量低或中等。
  • 预防性呼吸物理治疗:与PPCs降低相关(RR 0.55,95%CI 0.32-0.93),证据质量低或中等。
  • 硬膜外镇痛:与PPCs降低相关(RR 0.77,95%CI 0.65-0.92),证据质量低或中等。
  • 目标导向血流动力学治疗:与PPCs降低相关(RR 0.87,95%CI 0.77-0.98),证据质量低或中等。
  • 激励式肺量计:中等质量证据显示对预防PPCs无获益。

研究设计与关键结果

  • 系统评价与Meta分析纳入117项随机对照试验共21940例接受非心脏手术的成人患者,评估11类围手术期干预;95项试验共18062例进入Meta分析,22项因干预措施不够相似未能合并而未纳入。
  • 主要结局为PPCs发生率;未发现高质量证据支持任何干预降低PPCs。
  • 7种干预有低或中等质量证据提示可能降低PPCs:加速康复路径(RR 0.35,95%CI 0.21-0.58)、预防性黏液溶解剂(RR 0.40,95%CI 0.23-0.67)、术后持续气道正压通气(RR 0.49,95%CI 0.24-0.99)、肺保护性术中通气(RR 0.52,95%CI 0.30-0.88)、预防性呼吸物理治疗(RR 0.55,95%CI 0.32-0.93)、硬膜外镇痛(RR 0.77,95%CI 0.65-0.92)、目标导向血流动力学治疗(RR 0.87,95%CI 0.77-0.98)。
  • 中等质量证据显示激励式肺量计对预防PPCs无获益。
  • 试验序贯分析校正后,预防性呼吸物理治疗、硬膜外镇痛、加速康复路径和目标导向血流动力学治疗可自信支持PPCs相对风险降低25%;其他干预数据不足,无法支持或反驳等效的相对风险降低。
  • 次要结局包括呼吸道感染、肺不张、住院时间和死亡率;未测量或比较干预的不良反应。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入随机对照试验,证据质量按GRADE方法总结。
  • 证据质量:总体以低质量证据为主,未发现高质量证据;7种干预为低或中等质量证据,激励式肺量计为中等质量证据显示无获益。
  • 局限:未测量或比较干预的不良反应;22项试验因干预措施不够相似未能合并入Meta分析;许多干预需低偏倚风险的新试验才能获得确切疗效证据(原文结论指出)。

对床旁实践的改变

  • 作者认为临床医生可重新评估其围手术期管理路径,但结果提示许多干预仍需低偏倚风险的新试验才能获得确切疗效证据。
  • 对于非心脏手术成人患者,低或中等质量证据提示加速康复路径、预防性黏液溶解剂、术后持续气道正压通气、肺保护性术中通气、预防性呼吸物理治疗、硬膜外镇痛和目标导向血流动力学治疗可能降低PPCs。
  • 中等质量证据显示激励式肺量计对预防PPCs无获益。
  • 未发现高质量证据支持任何干预降低PPCs;未测量或比较干预的不良反应。

指南或共识出处

  • 系统评价与Meta分析,注册号PROSPERO CRD42016035662,发表于BMJ。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To identify, appraise, and synthesise the best available evidence on the efficacy of perioperative interventions to reduce postoperative pulmonary complications (PPCs) in adult patients undergoing non-cardiac surgery.

DESIGN: Systematic review and meta-analysis of randomised controlled trials.

DATA SOURCES: Medline, Embase, CINHAL, and CENTRAL from January 1990 to December 2017.

ELIGIBILITY CRITERIA: Randomised controlled trials investigating short term, protocolised medical interventions conducted before, during, or after non-cardiac surgery were included. Trials with clinical diagnostic criteria for PPC outcomes were included. Studies of surgical technique or physiological or biochemical outcomes were excluded.

DATA EXTRACTION AND SYNTHESIS: Reviewers independently identified studies, extracted data, and assessed the quality of evidence. Meta-analyses were conducted to calculate risk ratios with 95% confidence intervals. Quality of evidence was summarised in accordance with GRADE methods. The primary outcome was the incidence of PPCs. Secondary outcomes were respiratory infection, atelectasis, length of hospital stay, and mortality. Trial sequential analysis was used to investigate the reliability and conclusiveness of available evidence. Adverse effects of interventions were not measured or compared.

RESULTS: 117 trials enrolled 21 940 participants, investigating 11 categories of intervention. 95 randomised controlled trials enrolling 18 062 participants were included in meta-analysis; 22 trials were excluded from meta-analysis because the interventions were not sufficiently similar to be pooled. No high quality evidence was found for interventions to reduce the primary outcome (incidence of PPCs). Seven interventions had low or moderate quality evidence with confidence intervals indicating a probable reduction in PPCs: enhanced recovery pathways (risk ratio 0.35, 95% confidence interval 0.21 to 0.58), prophylactic mucolytics (0.40, 0.23 to 0.67), postoperative continuous positive airway pressure ventilation (0.49, 0.24 to 0.99), lung protective intraoperative ventilation (0.52, 0.30 to 0.88), prophylactic respiratory physiotherapy (0.55, 0.32 to 0.93), epidural analgesia (0.77, 0.65 to 0.92), and goal directed haemodynamic therapy (0.87, 0.77 to 0.98). Moderate quality evidence showed no benefit for incentive spirometry in preventing PPCs. Trial sequential analysis adjustment confidently supported a relative risk reduction of 25% in PPCs for prophylactic respiratory physiotherapy, epidural analgesia, enhanced recovery pathways, and goal directed haemodynamic therapies. Insufficient data were available to support or refute equivalent relative risk reductions for other interventions.

CONCLUSIONS: Predominantly low quality evidence favours multiple perioperative PPC reduction strategies. Clinicians may choose to reassess their perioperative care pathways, but the results indicate that new trials with a low risk of bias are needed to obtain conclusive evidence of efficacy for many of these interventions.

STUDY REGISTRATION: Prospero CRD42016035662.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Odor PM, Bampoe S, Gilhooly D, et al. Perioperative interventions for prevention of postoperative pulmonary complications: systematic review and meta-analysis. BMJ. 2020. PMID: 32161042. doi:10.1136/bmj.m540

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。